Polar Capital Holdings Plc boosted its position in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK – Free Report) by 66.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,322,011 shares of the company’s stock after acquiring an additional 527,929 shares during the period. Polar Capital Holdings Plc owned approximately 1.30% of Scholar Rock worth $58,235,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in SRRK. IFP Advisors Inc lifted its position in shares of Scholar Rock by 294.1% in the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after acquiring an additional 450 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Scholar Rock in the fourth quarter valued at $30,000. Ramirez Asset Management Inc. acquired a new position in shares of Scholar Rock in the third quarter valued at $37,000. EverSource Wealth Advisors LLC lifted its position in Scholar Rock by 151.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after purchasing an additional 525 shares during the period. Finally, Hilton Head Capital Partners LLC acquired a new stake in Scholar Rock during the fourth quarter worth $44,000. Institutional investors and hedge funds own 91.08% of the company’s stock.
Insider Activity
In other news, CFO Vikas Sinha sold 10,410 shares of the firm’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total transaction of $516,023.70. Following the completion of the sale, the chief financial officer owned 619,856 shares of the company’s stock, valued at approximately $30,726,261.92. This trade represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Keith Woods sold 10,220 shares of Scholar Rock stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total transaction of $506,605.40. Following the completion of the transaction, the chief operating officer owned 620,055 shares of the company’s stock, valued at $30,736,126.35. This trade represents a 1.62% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 63,491 shares of company stock valued at $3,147,249 over the last three months. 13.30% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
View Our Latest Report on SRRK
Scholar Rock Stock Down 0.8%
Shares of NASDAQ:SRRK opened at $45.56 on Wednesday. The company’s fifty day moving average is $47.71 and its 200-day moving average is $45.90. The company has a debt-to-equity ratio of 0.71, a quick ratio of 8.64 and a current ratio of 8.64. Scholar Rock Holding Corporation has a 52 week low of $27.07 and a 52 week high of $52.19. The company has a market capitalization of $5.46 billion, a PE ratio of -12.69 and a beta of 0.69.
Scholar Rock (NASDAQ:SRRK – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same period last year, the company earned ($0.67) EPS. Equities research analysts predict that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current fiscal year.
About Scholar Rock
Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.
The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).
Featured Articles
- Five stocks we like better than Scholar Rock
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.
